RE: Letter to the Editor “Practical Issues with Using Direct Oral Anticoagulant After Bariatric Metabolic Surgery” Following the Publication of: “30-Day Post-Discharge Prophylaxis with Rivaroxaban Prevents PMVT Following Laparoscopic Sleeve Gastrectomy”-Reference-Cited by-同舟云学术

RE: Letter to the Editor “Practical Issues with Using Direct Oral Anticoagulant After Bariatric Metabolic Surgery” Following the Publication of: “30-Day Post-Discharge Prophylaxis with Rivaroxaban Prevents PMVT Following Laparoscopic Sleeve Gastrectomy”

Published:2023-04-21 Issue:6 Volume:33 Page:1930-1931
ISSN:0960-8923
Container-title:Obesity Surgery
language:en
Short-container-title:OBES SURG

Author:

Swartz Daniel E.^ORCID,Gupta Sachin

Publisher

Springer Science and Business Media LLC

Subject

Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s11695-023-06592-5.pdf

Reference6 articles.

1. Swartz DE, Hood L, Swartz DR, et al. 30-day post-discharge prophylaxis with rivaroxaban prevents porto-mesenteric venous thrombosis following laparoscopic sleeve gastrectomy. Obes Surg. 2023;3(4):1026–31.

2. Nasser MF, Jabri A, Gandhi S, et al. Oral anticoagulant use in morbid obesity and post bariatric surgery: a review. Am J Med. 2021;134(12):1465-75.

3. Rosovsky RP, Kline-Rogers E, Lake L, et al. Direct oral anticoagulants in obest patients with venous thromboembolism: results of an expert consensus panel. Am J Med. 2023.

4. Martin KA, Lee CR, Farrell TM, et al. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. Am J Med. 2017;130(5):517–24.

5. Aminian A, Vosburg RW, Altiere MS, et al. American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolic prophylaxis in bariatric surgery. Surg Obes Relat Dis. 2022;18(2):165–74.